Ovarian Mucinous, Brenner Tumors, and Other Epithelial Tumors

  • Cathleen Matrai
  • Taylor M. Jenkins
  • Esther Baranov
  • Lauren E. SchwartzEmail author


In this chapter we cover a wide variety of ovarian lesions. While the majority of the chapter focuses on mucinous neoplasms of the ovary, we also discuss Brenner tumors and cover a wide range of rare ovarian neoplasms that every pathologist should be familiar with. This chapter emphasizes the differential diagnosis of these entities and keys to case workup and diagnosis.


Mucinous Brenner Borderline Carcinoma Wolffian Small Cell 


  1. 1.
    Chen VW, et al. Pathology and classification of ovarian tumors. Cancer. 2003;97(10 Suppl):2631–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep. 2014;16(6):389.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Kurman RJ, Shih Ie M. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–47.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Hauptmann S, et al. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch. 2017;470(2):125–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Hart WR. Mucinous tumors of the ovary: a review. Int J Gynecol Pathol. 2005;24(1):4–25.Google Scholar
  6. 6.
    Milea A, et al. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. Mod Pathol. 2014;27(7):991–1001.PubMedCrossRefGoogle Scholar
  7. 7.
    Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer. 1973;31(5):1031–45.PubMedCrossRefGoogle Scholar
  8. 8.
    Han G, Soslow RA. Nonserous ovarian epithelial tumors. Surg Pathol Clin. 2011;4(1):397–459.PubMedCrossRefGoogle Scholar
  9. 9.
    Tait DL, Miller DS. Multicystic ovarian tumor weighing 156 lbs: the second largest tumor in Texas. Tex Med. 1997;93(1):89–91.PubMedGoogle Scholar
  10. 10.
    Seidman JD, Khedmati F. Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med. 2008;132(11):1753–60.PubMedGoogle Scholar
  11. 11.
    Czernobilsky B, Borenstein R, Lancet M. Cystadenofibroma of the ovary. A clinicopathologic study of 34 cases and comparison with serous cystadenoma. Cancer. 1974;34(6):1971–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Kao GF, Norris HJ. Unusual cystadenofibromas: endometrioid, mucinous, and clear cell types. Obstet Gynecol. 1979;54(6):729–36.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Randrianjafisamindrakotroka NS, Gasser B, Philippe E. [The malignant potential of adenofibroma and cystadenofibroma of the ovary and mesovarium. 118 cases including 13 proliferative and 5 carcinomatous]. J Gynecol Obstet Biol Reprod (Paris). 1993;22(1):33–8.Google Scholar
  14. 14.
    Lee DH. A case of mucinous cystadenofibroma of the ovary. Case Rep Obstet Gynecol. 2014;2014:130530.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Roma AA, Masand RP. Different staining patterns of ovarian Brenner tumor and the associated mucinous tumor. Ann Diagn Pathol. 2015;19(1):29–32.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Kondi-Pafiti A, et al. Clinicopathological features and immunoprofile of 30 cases of Brenner ovarian tumors. Arch Gynecol Obstet. 2012;285(6):1699–702.PubMedCrossRefGoogle Scholar
  17. 17.
    Rambau PF, et al. Morphologic reproducibility, genotyping, and Immunohistochemical profiling do not support a category of seromucinous carcinoma of the ovary. Am J Surg Pathol. 2017;41(5):685–95.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Li XS, Sun J, He XL. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors. Genet Mol Res. 2015;14(3):10752–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Auner V, et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer. 2009;9:111.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Lee YJ, et al. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms. Oncotarget. 2016;7(50):82097–103.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Robert J. Kurman, Carcangiu, M.L., C. Simon Herrington, Robert H. Young, WHO classification of tumours of female reproductive organs. 4th ed. 2014, Lyon: IARC Press.Google Scholar
  22. 22.
    Kamel RM. A massive ovarian mucinous cystadenoma: a case report. Reprod Biol Endocrinol. 2010;8:24.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Mizrachi Y, et al. Intraoperative rupture of benign mucinous cystadenoma does not increase its recurrence rate. Arch Gynecol Obstet. 2015;291(5):1135–9.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Ben-Ami I, et al. Does intraoperative spillage of benign ovarian mucinous cystadenoma increase its recurrence rate? Am J Obstet Gynecol. 2010;202(2):142 e1–5.CrossRefGoogle Scholar
  25. 25.
    Chao A, et al. Abdominal compartment syndrome secondary to ovarian mucinous cystadenoma. Obstet Gynecol. 2004;104(5 Pt 2):1180–2.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Boger-Megiddo I, Weiss NS. Histologic subtypes and laterality of primary epithelial ovarian tumors. Gynecol Oncol. 2005;97(1):80–3.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‘pseudomyxoma peritonei’. Am J Surg Pathol. 2000;24(11):1447–64.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999;23(6):617–35.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol. 2005;18(Suppl 2):S33–50.PubMedCrossRefGoogle Scholar
  30. 30.
    Kurman RJ, Shih Ie M. Seromucinous tumors of the ovary. What’s in a name? Int J Gynecol Pathol. 2016;35(1):78–81.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Vang R, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol. 2006;19(11):1421–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Mackenzie R, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer. 2015;15:415.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Cuatrecasas M, et al. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer. 1997;79(8):1581–6.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Ryland GL, et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med. 2015;7(1):87.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Ronnett BM, et al. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol. 2004;35(8):949–60.PubMedCrossRefGoogle Scholar
  36. 36.
    De Decker K, et al. Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease. Gynecol Oncol. 2017;144(2):285–9.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Dewilde K, et al. Staging with unilateral Salpingo-oophorectomy and expert pathological review result in no recurrences in a series of 81 intestinal-type mucinous borderline ovarian tumors. Gynecol Obstet Investig. 2018;83(1):65–9.CrossRefGoogle Scholar
  38. 38.
    Gungorduk K, et al. The impact of surgical staging on the prognosis of mucinous borderline tumors of the ovaries: a multicenter study. Anticancer Res. 2017;37(10):5609–16.PubMedGoogle Scholar
  39. 39.
    Uzan C, et al. Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments. Ann Oncol. 2014;25(7):1312–9.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Khunamornpong S, et al. Mucinous tumor of low malignant potential (“borderline” or “atypical proliferative” tumor) of the ovary: a study of 171 cases with the assessment of intraepithelial carcinoma and microinvasion. Int J Gynecol Pathol. 2011;30(3):218–30.PubMedCrossRefGoogle Scholar
  41. 41.
    Vasconcelos I, Darb-Esfahani S, Sehouli J. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates. BJOG. 2016;123(4):498–508.PubMedCrossRefGoogle Scholar
  42. 42.
    Khunamornpong S, Russell P, Dalrymple JC. Proliferating (LMP) mucinous tumors of the ovaries with microinvasion: morphologic assessment of 13 cases. Int J Gynecol Pathol. 1999;18(3):238–46.PubMedCrossRefGoogle Scholar
  43. 43.
    Kim KR, et al. Is stromal microinvasion in primary mucinous ovarian tumors with “mucin granuloma” true invasion? Am J Surg Pathol. 2007;31(4):546–54.PubMedCrossRefGoogle Scholar
  44. 44.
    Rouzbahman M, Chetty R. Mucinous tumours of appendix and ovary: an overview and evaluation of current practice. J Clin Pathol. 2014;67(3):193–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Panarelli NC, Yantiss RK. Mucinous neoplasms of the appendix and peritoneum. Arch Pathol Lab Med. 2011;135(10):1261–8.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Ramaswamy V. Pathology of mucinous appendiceal tumors and pseudomyxoma peritonei. Indian J Surg Oncol. 2016;7(2):258–67.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Young RH, Gilks CB, Scully RE. Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol. 1991;15(5):415–29.PubMedCrossRefGoogle Scholar
  48. 48.
    Ronnett BM, et al. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol. 1995;19(12):1390–408.PubMedCrossRefGoogle Scholar
  49. 49.
    Cuatrecasas M, Matias-Guiu X, Prat J. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Am J Surg Pathol. 1996;20(6):739–46.PubMedCrossRefGoogle Scholar
  50. 50.
    Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol. 2003;27(5):650–7.CrossRefGoogle Scholar
  51. 51.
    Prat J, Scully RE. Ovarian mucinous tumors with sarcoma-like mural nodules: a report of seven cases. Cancer. 1979;44(4):1332–44.PubMedCrossRefGoogle Scholar
  52. 52.
    Prat J, Young RH, Scully RE. Ovarian mucinous tumors with foci of anaplastic carcinoma. Cancer. 1982;50(2):300–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Provenza C, Young RH, Prat J. Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules. Am J Surg Pathol. 2008;32(3):383–9.PubMedCrossRefGoogle Scholar
  54. 54.
    McFarland M, et al. Osteosarcoma as malignant mural nodule in ovarian mucinous neoplasms of intestinal type: report of 2 cases. Int J Gynecol Pathol. 2015;34(4):369–73.PubMedCrossRefGoogle Scholar
  55. 55.
    Balaton A, et al. Primary leiomyosarcoma of the ovary: a histological and immunocytochemical study. Gynecol Oncol. 1987;28(1):116–20.PubMedCrossRefGoogle Scholar
  56. 56.
    WHO classification of tumours of femal reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer.Google Scholar
  57. 57.
    Ledermann JA, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S14–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Zaino RJ, et al. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer. 2011;117(3):554–62.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Yemelyanova AV, et al. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol. 2008;32(1):128–38.PubMedCrossRefGoogle Scholar
  60. 60.
    Chen S, et al. Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol. 2005;18(7):903–11.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Santotoribio JD, et al. Serum lactate dehydrogenase in combination with free-to-total serum prostate specific antigen ratio for diagnosis of prostate cancer. Clin Lab. 2014;60(6):1055–8.PubMedGoogle Scholar
  62. 62.
    Cho HY, Kyung MS. Serum CA19-9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case-control study. Med Sci Monit. 2014;20:1334–9.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12(11):1071–80.PubMedCrossRefGoogle Scholar
  64. 64.
    Anglesio MS, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229(1):111–20.PubMedCrossRefGoogle Scholar
  65. 65.
    Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27(7):985–93.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Hu A, et al. Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality. J Clin Pathol. 2015;68(7):522–8.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Perez Montiel D, et al. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic. Ann Diagn Pathol. 2015;19(4):249–52.PubMedCrossRefGoogle Scholar
  68. 68.
    Meriden Z, et al. Ovarian metastases of pancreaticobiliary tract adenocarcinomas: analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors. Am J Surg Pathol. 2011;35(2):276–88.PubMedCrossRefGoogle Scholar
  69. 69.
    Vang R, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol. 2006;19(1):97–105.PubMedCrossRefGoogle Scholar
  70. 70.
    McCluggage WG. Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms. J Clin Pathol. 2012;65(7):596–600.PubMedCrossRefGoogle Scholar
  71. 71.
    Arnogiannaki N, et al. Proliferative Brenner tumor of the ovary. Clinicopathological study of two cases and review of the literature. Eur J Gynaecol Oncol. 2011;32(5):576–8.PubMedGoogle Scholar
  72. 72.
    Fox H, Agrawal K, Langley FA. The Brenner tumour of the ovary. A clinicopathological study of 54 cases. J Obstet Gynaecol Br Commonw. 1972;79(7):661–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Kuhn E, et al. Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. Eur J Cancer. 2013;49(18):3839–49.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Seidman JD, et al. The fallopian tube-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol. 2011;30(1):4–11.PubMedCrossRefGoogle Scholar
  75. 75.
    Ali RH, et al. Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant Brenner tumor. Int J Gynecol Pathol. 2012;31(6):499–506.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Ruggiero S, et al. A singular observation of a giant benign Brenner tumor of the ovary. Arch Gynecol Obstet. 2011;284(2):513–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Burg J, et al. Mature cystic teratoma of the ovary with struma and benign Brenner tumor: a case report with immunohistochemical characterization. Int J Gynecol Pathol. 2002;21(1):74–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Takeuchi K, et al. Coexistence of brenner tumor and struma ovarii: case report. Eur J Gynaecol Oncol. 2005;26(1):109–10.PubMedGoogle Scholar
  79. 79.
    Yoshida M, et al. Coexisting Brenner tumor and struma ovarii in the right ovary: case report and review of the literature. Pathol Int. 2004;54(10):793–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Tafe LJ, et al. Molecular genetic analysis of ovarian Brenner Tumors and associated mucinous epithelial neoplasms. High variant concordance and identification of mutually exclusive RAS driver mutations and MYC amplification. Am J Pathol. 2016;186(3):671–7.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Wang Y, et al. Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin. J Pathol. 2015;237(2):146–51.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Santini D, et al. Brenner tumor of the ovary: a correlative histologic, histochemical, immunohistochemical, and ultrastructural investigation. Hum Pathol. 1989;20(8):787–95.PubMedCrossRefGoogle Scholar
  83. 83.
    Cuatrecasas M, et al. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer. 1998;82(6):1088–95.PubMedCrossRefGoogle Scholar
  84. 84.
    Pejovic T, et al. Well-differentiated mucinous carcinoma of the ovary and a coexisting Brenner tumor both exhibit amplification of 12q14-21 by comparative genomic hybridization. Gynecol Oncol. 1999;74(1):134–7.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Ogawa K, Johansson SL, Cohen SM. Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract. Am J Pathol. 1999;155(4):1047–50.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Egan AJ, Russell P. Transitional (urothelial) cell metaplasia of the fallopian tube mucosa: morphological assessment of three cases. Int J Gynecol Pathol. 1996;15(1):72–6.PubMedCrossRefGoogle Scholar
  87. 87.
    Rabban JT, et al. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women with BRCA mutations. Am J Surg Pathol. 2009;33(1):111–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Chia CC, Huang SC. A borderline ovarian Brenner tumor mimics uterine fibroids. Taiwan J Obstet Gynecol. 2011;50(1):103–5.PubMedCrossRefGoogle Scholar
  89. 89.
    Kuhn E, et al. The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. Mod Pathol. 2014;27(2):231–7.PubMedCrossRefGoogle Scholar
  90. 90.
    De Cecio R, et al. Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study. J Ovarian Res. 2014;7:101.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol. 2002;26(11):1477–83.PubMedCrossRefGoogle Scholar
  92. 92.
    Gordon MD, et al. CD99, keratin, and vimentin staining of sex cord-stromal tumors, normal ovary, and testis. Mod Pathol. 1998;11(8):769–73.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Nasioudis D, et al. Malignant Brenner tumors of the ovary; a population-based analysis. Gynecol Oncol. 2016;142(1):44–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Austin RM, Norris HJ. Malignant Brenner tumor and transitional cell carcinoma of the ovary: a comparison. Int J Gynecol Pathol. 1987;6(1):29–39.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Badve S, et al. Malignant Brenner tumor mimicking a primary squamous cell carcinoma of the cervix. Gynecol Oncol. 1999;74(3):487–90.PubMedCrossRefGoogle Scholar
  96. 96.
    Vemavarapu L, Alatassi H, Moghadamfalahi M. Unusual presentation of benign cystic brenner tumor with exuberant psammomatous calcifications. Int J Surg Pathol. 2011;19(1):120–2.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Roth LM, Goheen MP, Broshears JR. Malignant Brenner tumor of the ovary with transformation to trabecular carcinoid: an immunocytochemical and electron microscopic study. Int J Gynecol Pathol. 2012;31(1):91–7.PubMedCrossRefGoogle Scholar
  98. 98.
    Srivastava H, et al. Pure primary squamous cell carcinoma of ovary—a rare case report. J Clin Diagn Res. 2017;11(5):QD01–2.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Pins MR, et al. Primary squamous cell carcinoma of the ovary. Report of 37 cases. Am J Surg Pathol. 1996;20(7):823–33.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Park JW, Bae JW. Pure primary ovarian squamous cell carcinoma: a case report and review of the literature. Oncol Lett. 2015;9(1):321–3.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Witkowski L, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 2014;46(5):438.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Aguirre P, Thor AD, Scully RE. Ovarian small cell carcinoma. Histogenetic considerations based on immunohistochemical and other findings. Am J Clin Pathol. 1989;92(2):140–9.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    McCluggage W, et al. An immunohistochemical analysis of ovarian small cell carcinoma of hypercalcemic type. Int J Gynecol Pathol. 2004;23(4):330–6.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    McCluggage WG, et al. Clinical, morphological and immunohistochemical evidence that small-cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) may be a primitive germ-cell neoplasm. Histopathology. 2017;70(7):1147–54.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Witkowski L, et al. Small-cell carcinoma of the ovary of hypercalcemic type (malignant rhabdoid tumor of the ovary): a review with recent developments on pathogenesis. 2016: United States. Surg Pathol Clin. 2016;9(2):215–26.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Young RH, Oliva E, Scully RE. Small-cell carcinoma of the ovary, hypercalcaemic type. A clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;18(11):1102–16.CrossRefGoogle Scholar
  107. 107.
    Estel R, et al. Small cell carcinoma of the ovary of the hypercalcaemic type: an analysis of clinical and prognostic aspects of a rare disease on the basis of cases published in the literature. Arch Gynecol Obstet. 2011;284:1277–82.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Lavrut PM, et al. Small cell carcinoma of the ovary, hypercalcemic type: report of a bilateral case in a teenager associated with SMARCA4 germline mutation. Pediatr Dev Pathol. 2016;19(1):56–60.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Callegaro-Filho D, et al. Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT): a review of 47 cases. Gynecol Oncol. 2016;140(1):53–7.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Witkowski L, et al. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecol Oncol. 2016;141(3):454–60.PubMedCrossRefGoogle Scholar
  111. 111.
    Agarwal L, Gupta B, Jain A. Pure large cell neuroendocrine carcinoma of the ovary with metastasis to cervix: a rare case report and review of literature. J Clin Diagn Res. 2016;10(9):ED03.Google Scholar
  112. 112.
    Veras E, et al. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol. 2007;31(5):774–82.PubMedCrossRefGoogle Scholar
  113. 113.
    Lindboe CF. Large cell neuroendocrine carcinoma of the ovary. APMIS. 2007;115(2):169.PubMedCrossRefGoogle Scholar
  114. 114.
    Kwon YS, Im KS, Choi DI. Ovarian large cell neuroendocrine carcinoma in the youngest woman. Eur J Gynaecol Oncol. 2016;37(2):244.PubMedGoogle Scholar
  115. 115.
    Randolph LK, et al. Hepatoid carcinoma of the ovary: a case report and review of the literature. Gynecol Oncol Rep. 2015;13:64–7.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Ishikura H, Scully RE. Hepatoid carcinoma of the ovary. A newly described tumor. Cancer. 1987;60(11):2775–84.PubMedCrossRefGoogle Scholar
  117. 117.
    Tochigi N, et al. Hepatoid carcinoma of the ovary: a report of three cases admixed with a common surface epithelial carcinoma. Int J Gynecol Pathol. 2003;22(3):266–71.PubMedCrossRefGoogle Scholar
  118. 118.
    Pitman MB, et al. Hepatocyte paraffin 1 antibody does not distinguish primary ovarian tumors with hepatoid differentiation from metastatic hepatocellular carcinoma. Int J Gynecol Pathol. 2004;23(1):58–64.PubMedGoogle Scholar
  119. 119.
    Scully RE, Young R, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Vol. 23, 3rd ser. 1998; Washington, DC: Armed Forces Institute of Pathology.Google Scholar
  120. 120.
    Scurry JP, Brown RW, Jobling T. Combined ovarian serous papillary and hepatoid carcinoma. Gynecol Oncol. 1996;63(1):138–42.PubMedCrossRefGoogle Scholar
  121. 121.
    Sung JH, et al. Hepatoid carcinoma of the ovary without staining for alpha-fetoprotein. Obstet Gynecol Sci. 2013;56(1):41–4.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Young RH, et al. Hepatocellular carcinoma metastatic to the ovary: a report of three cases discovered during life with discussion of the differential diagnosis of hepatoid tumors of the ovary. Hum Pathol. 1992;23(5):574–80.PubMedCrossRefGoogle Scholar
  123. 123.
    Rutgers JL, Scully RE. Cysts (cystadenomas) and tumors of the rete ovarii. Int J Gynecol Pathol. 1988;7(4):330–42.PubMedCrossRefGoogle Scholar
  124. 124.
    Heatley MK. Adenomatous hyperplasia of the rete ovarii. Histopathology. 2000;36(4):383–4.PubMedCrossRefGoogle Scholar
  125. 125.
    Nogales FF, et al. Adenomas of the rete ovarii. Hum Pathol. 1997;28(12):1428–33.PubMedCrossRefGoogle Scholar
  126. 126.
    Goyal A, Masand RP, Roma AA. Value of PAX-8 and SF-1 immunohistochemistry in the distinction between female adnexal tumor of probable Wolffian origin and its mimics. Int J Gynecol Pathol. 2016;35(2):167–75.CrossRefGoogle Scholar
  127. 127.
    Sangoi AR, et al. Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases. Mod Pathol. 2009;22(9):1228–35.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Young R, Silva E, Scully R. Ovarian and Juxtaovarian Adenomatoid Tumors: a report of six cases. Int J Gynecol Pathol. 1991;10(4):364–71.PubMedCrossRefGoogle Scholar
  129. 129.
    Clement PB, Young RH, Scully RE. Malignant mesotheliomas presenting as ovarian masses. A report of nine cases, including two primary ovarian mesotheliomas. Am J Surg Pathol. 1996;20(9):1067–80.CrossRefGoogle Scholar
  130. 130.
    Goode B, et al. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Mod Pathol. 2018;31(4):660–73.PubMedCrossRefGoogle Scholar
  131. 131.
    Tangjitgamol S, et al. Huge peritoneal malignant mesothelioma mimicking primary ovarian carcinoma. J Med Assoc Thail. 2013;96(1):107–11.Google Scholar
  132. 132.
    Kapoor R, et al. A case report of peritoneal malignant mesothelioma presenting as primary ovarian mass. J Cancer Res Ther. 2015;11(3):654.PubMedCrossRefGoogle Scholar
  133. 133.
    Tandon R, et al. Immunohistochemistry in peritoneal mesothelioma: a single-center experience of 244 cases. Arch Pathol Lab Med. 2018;142(2):236–42.PubMedCrossRefGoogle Scholar
  134. 134.
    Chapel DB, et al. PAX8 expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma. Am J Surg Pathol. 2017;41(12):1675–82.CrossRefGoogle Scholar
  135. 135.
    Andrici J, et al. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol. 2016;51:9–15.CrossRefGoogle Scholar
  136. 136.
    Ota S, et al. Desmoplastic small round cell tumor in the ovary: report of two cases and literature review. J Obstet Gynaecol Res. 2010;36(2):430–4.PubMedCrossRefGoogle Scholar
  137. 137.
    Nakayama J, et al. Desmoplastic small round cell tumor of the ovary: a rare but devastating disease in young women. Gynecol Oncol Case Rep. 2014;7:16–8.PubMedCrossRefGoogle Scholar
  138. 138.
    Mora J, et al. Desmoplastic small round cell tumor 20 years after its discovery. Future Oncol. 2015;11(7):1071–81.PubMedCrossRefGoogle Scholar
  139. 139.
    Neff RT, et al. Management of a rapidly enlarging new adnexal mass: a rare case of desmoplastic small round cell tumor of the ovary arising in pregnancy. Gynecol Oncol Rep. 2016;17:23–5.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    D'Ippolito G, Huizing MT, Tjalma WAA. Desmoplastic small round cell tumor (DSRCT) arising in the ovary: report of a case diagnosed at an early stage and review of the literature. Eur J Gynaec Oncol. 2012;33(1):96.Google Scholar
  141. 141.
    Young RH, et al. Ovarian involvement by the intra-abdominal desmoplastic small round cell tumor with divergent differentiation: a report of three cases. Hum Pathol. 1992;23(4):454–64.CrossRefGoogle Scholar
  142. 142.
    Thway K, et al. Desmoplastic small round cell tumor: pathology, genetics, and potential therapeutic strategies. Los Angeles: SAGE Publications; 2016. p. 672–84.Google Scholar
  143. 143.
    Cossu A, et al. Female adnexal tumors of probable Wolffian origin (FATWO): a case series with next-generation sequencing mutation analysis. Int J Gynecol Pathol. 2017;36(6):575–81.PubMedCrossRefGoogle Scholar
  144. 144.
    Devouassoux-Shisheboran M, Silver SA, Tavassoli FA. Wolffian adnexal tumor, so-called female adnexal tumor of probable Wolffian origin (FATWO): immunohistochemical evidence in support of a Wolffian origin. Hum Pathol. 1999;30(7):856.PubMedCrossRefGoogle Scholar
  145. 145.
    Ramirez PT, et al. Wolffian duct tumors: case reports and review of the literature. Gynecol Oncol. 2002;86(2):225–30.PubMedCrossRefGoogle Scholar
  146. 146.
    Hong S, et al. Malignant female adnexal tumor of probable Wolffian origin: case report and literature review. Int J Gynecol Pathol. 2017;00:1–7.Google Scholar

Copyright information

© Science Press & Springer Nature Singapore Pte Ltd.  2019

Authors and Affiliations

  • Cathleen Matrai
    • 1
  • Taylor M. Jenkins
    • 2
  • Esther Baranov
    • 2
  • Lauren E. Schwartz
    • 2
    Email author
  1. 1.Weill Cornell Medical College, Cornell University and New York-Presbyterian HospitalNew YorkUSA
  2. 2.Penn MedicineUniversity of Pennsylvania Heath SystemPhiladelphiaUSA

Personalised recommendations